Biologic Therapies III
Patient with Hepatitis B
and Rheumatoid
Arthritis
 |
||
|
How to Obtain AMA PRA
|
|
 |
||
Release Date: June 5, 2009
Expiration Date: June 5, 2011
Estimated Time of Completion: 30 minutes
Description
The Biologics Therapies Summit III Mini-Symposium Master Clinician Panel was captured and repurposed into a case-based format to discuss the management strategies for clinicians caring for patients with rheumatic and inflammatory diseases. The cases include autoimmune and inflammatory disorders, common and rare infections associated with biologics, newer agents, and biologic use with existing conditions such as, cancer, and liver disease.
Objectives
At the conclusion of this activity, the participant will be able to:
- Identify the relevant factors for determining management strategies for a patient with RA who has hepatitis B.
- Review safety data concerning the use of conventional or biologic disease-modifying antirheumatic drugs (DMARDs) in a patient with RA who has hepatitis B.
- Discuss treatment options for a patient with RA who has hepatitis B.
Target Audience
This case-based series is directed toward rheumatologists, gastroenterologists, dermatologists, pulmonologists, internal medicine physicians, nurse practitioners, physician assistants, and other healthcare professionals interested in or using biologic therapeutics in autoimmune and inflammatory disorders.
Accreditation
The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for Category 2 credit.
Activity Director
Leonard Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
of Case Western Reserve University
Vice Chairman
Department of Rheumatic & Immunologic Diseases
R.J. Fasenmyer Chair of Clinical Immunology
Orthopaedic & Rheumatologic Institute
Cleveland Clinic
Faculty
| Leonard Calabrese, DO Professor of Medicine Cleveland Clinic Lerner College of Medicine of Case Western Reserve University Vice Chairman Department of Rheumatic & Immunologic Diseases R.J. Fasenmyer Chair of Clinical Immunology Orthopaedic & Rheumatologic Institute Cleveland Clinic Cleveland, Ohio |
Dimitrios Vassilopoulos, MD Assistant Professor of Medicine—Rheumatology Athens University School of Medicine Athens, Greece |
Faculty Disclosure
In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.
The following faculty has indicated that he may have a relationship that, in the context of his presentation, could be perceived as a potential conflict of interest:
| Leonard Calabrese, DO | ||
| Consulting |
Elan, Roche |
|
| Consulting, Teaching & Speaking |
Abbott, Amgen, Centocor, Genentech, Wyeth |
|
The following faculty has indicated he has no relationship which, in the context of his presentations, could be perceived as a potential conflict of interest:
Dimitrios Vassilopoulos, MD
The Cleveland Clinic Foundation Center for Continuing Education acknowledges educational
grants for partial support of this activity from:
Abbott Laboratories, Amgen, Centocor Ortho Biotech, Genentech and Biogen Idec,
Roche Laboratories, Inc., UCB, Inc., Wyeth
This CME activity was produced by The Cleveland Clinic Foundation
Center for Continuing Education and UNITECH Communications®.
